廣告
香港股市 已收市

  • 恒指

    17,718.61
    +2.14 (+0.01%)
     

  • 國指

    6,331.86
    +7.81 (+0.12%)
     

  • 上證綜指

    2,967.40
    +21.55 (+0.73%)
     

  • 滬深300

    3,461.66
    +7.54 (+0.22%)
     

  • 美元

    7.8086
    -0.0002 (-0.00%)
     

  • 人民幣

    0.9295
    -0.0008 (-0.09%)
     

  • 道指

    39,164.06
    +36.26 (+0.09%)
     

  • 標普 500

    5,482.87
    +4.97 (+0.09%)
     

  • 納指

    17,858.68
    +53.53 (+0.30%)
     

  • 日圓

    0.0483
    +0.0000 (+0.02%)
     

  • 歐元

    8.3607
    +0.0028 (+0.03%)
     

  • 英鎊

    9.8720
    +0.0030 (+0.03%)
     

  • 紐約期油

    82.50
    +0.76 (+0.93%)
     

  • 金價

    2,340.10
    +3.50 (+0.15%)
     

  • Bitcoin

    61,439.44
    +294.88 (+0.48%)
     

  • CMC Crypto 200

    1,281.32
    -2.51 (-0.20%)
     

ResMed Stock Dives. Blame Eli Lilly’s Zepbound Trials for Sleep Apnea.

Josh Nathan-Kazis
·3 分鐘文章
ResMed Stock Dives. Blame Eli Lilly’s Zepbound Trials for Sleep Apnea.

Strong results from Eli Lilly’s obesity medicine in a sleep apnea trial could upset the sleep apnea industry, while greatly expanding insurance coverage for the Lilly drug. Shares of ResMed which sells CPAP machines that treat sleep apnea, were falling sharply Monday. ResMed’s stock was down 11% to $183.34 near midday, putting it on track for its largest decline since Aug. 4, when it dropped 19%, according to Dow Jones Market Data.

繼續閱讀